Form 4: BIODESIX CDO Reports RSU Vesting and Tax-Related Stock Sale

BIODESIX Chief Development Officer Gary Pestano reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax obligations.

Summary

• Gary Anthony Pestano, Chief Development Officer of BIODESIX INC (BDSX), reported transactions involving the company's common stock and restricted stock units (RSUs).
• On January 15, 2026, 805 shares of common stock were acquired through the vesting of RSUs.
• On January 16, 2026, 298 shares of common stock were sold at a weighted average price of $8.1493 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, Gary Pestano beneficially owns 8,446 shares of common stock and 1,609 restricted stock units.
• The reported numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.
• The RSUs vest in four successive equal annual installments, measured from January 15, 2024, contingent on continued service with the Issuer.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and a subsequent 'sell-to-cover' for tax purposes, which is generally considered neutral in sentiment as it is not a discretionary sale indicating a lack of confidence, nor a significant discretionary purchase.

Positives

• Vesting of 805 restricted stock units indicates a portion of executive compensation being realized.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary transaction.

Negatives

• A disposition of 298 shares, even for tax purposes, reduces the direct beneficial ownership of common stock by the Chief Development Officer.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, beyond the scheduled vesting of RSUs.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, compensation-related insider transaction and not a discretionary sale or purchase that would signal a change in management's confidence.
• Employees: The RSU vesting demonstrates the company's compensation structure for executives.

Next Steps

• Future vesting of remaining Restricted Stock Units in successive equal annual installments from January 15, 2024, subject to continued service.

Key Dates

Keywords

BIODESIX, BDSX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Tax-Related Sale, Gary Pestano, Chief Development Officer, Beneficial Ownership